Minimally invasive treatment of central nervous system diseases
BrainsGate is committed to developing innovative therapies for patients suffering from Central Nervous System (CNS) diseases. BrainsGate's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow. Building on its technology, the company has developed the ISS, based on a miniature electrode implanted at the roof of the mouth in a minimally invasive, local anesthesia procedure comparable to dental treatment.
BrainsGate is exploring several applications for its technology, and is currently focusing on treatment of acute ischemic stroke in a 24-hour window after onset of symptoms. The majority (87%) of strokes are ischemic. There is currently no treatment approved for use beyond a 3-6-hour window, and only about 5% of stroke victims arrive at hospitals and medical centers in time to receive treatment. Stroke is a leading cause of adult long-term disability and the third leading cause of death in the U.S.
Future applications for BrainsGate's platform include chronic SPG stimulation to treat vascular dementia, the second most common form of dementia in older adults after Alzheimer's disease. BrainsGate's headquarters are located in Caesarea, Israel.